ESCMID Warns of Antibiotic Armageddon in UK and Europe by 2025
![](/46/pdcnewsitem/03/44/08/1a9iXMU7XTlnY57.jpg)
The European Society of Clinical Microbiology and Infectious Disease (ESCMID) has warned that Britain and Europe collectively could face more than a million deaths in an impending "Antibiotic Armageddon” unless more is done to develop new cures, rapid diagnostics and preventative measures to combat the spread of drug-resistant diseases.
Experts at ESCMID issued the warning ahead of its annual conference — Copenhagen, 25–28 April — adding that without more money being spent on developing new drugs and the rationing of existing supplies, deaths across Europe could pass the grim milestone of a million by 2025. In Britain alone an estimated 10,000 people die a year and experts at ESCMID fear this number could triple, or even quadruple, within the next 10 years.
Currently, the best available figures were published back in 2009 and estimated that around 25–30,000 Europeans die each year due to antimicrobial resistance and the total number of deaths is now over 400,000. The European Centre for Disease Prevention and Control (ECDC) will make 2013 figures available later this year. However, due to new outbreaks with almost impossible to treat micro-organisms, ESCMID predicts that the current (true) mortality rate is almost certain to have risen significantly. Furthermore, ESCMID predicts that within the next 10 years, annual deaths in Europe could top 50,000 per year. The global position is even more critical, and by the year 2050, deaths per year are projected to rise to 10 million, surpassing major killers such as cancer, diabetes and road traffic accidents.
Murat Akova, ESCMID President, commenting on the scale of the problem: "The worrying aspect for Europe is that there is clearly a huge risk, particularly across some of the Mediterranean states. However, no one really knows just how big the problem currently is, let alone how big it’s going to become in the future. Although, we could see European national numbers remain broadly the same, it is far more likely to double, treble or even quadruple in the next 10 years. The other major problem is that bacteria do not respect country boundaries, so we are likely to see highly-resistant microbes spreading out from nations with a more severe problem. We need both European-wide and global strategies, as well as national initiatives, as the problem will not remain regionalised for long.”
The worst affected nations in Europe are Greece, Spain and Italy, which are facing an imminent antibiotic Armageddon, as an increasing number of bacteria within these countries are now resistant to most, or all, forms of known antibiotics. ESCMID cautions that this is not simply down to the lack of new antibiotics, but is being exacerbated by poor monitoring and control of drugs supply, and insufficient infection control in many hospitals and institutions. Worryingly, the implications of this change extend far beyond just a rising death toll, as it is fundamentally jeopardising modern healthcare, with costs rapidly increasing, and therapies and hospital stays being prolonged. The estimated global economic costs associated with this rise is $100 trillion, potentially resulting in a significant reduction in GDP [~6%] across all countries, with the poorest countries projected to experience the largest relative loss in GDP. The economic cost in Europe is already approximately €1.5 billion and rising.
Akova added: "Deaths in the UK alone could very easily triple over the next 10 years. But focusing only on the death toll by antimicrobial resistance obfuscates the gigantic problem of not being able to offer patients many of the modern healthcare victories. The rapid increase in antimicrobial resistance in Europe and the world is jeopardizing modern healthcare. And resistance is spreading to the UK from across other European nations.”
This year’s annual congress will again bring this issue into acute focus and the society is calling on governments and the pharma community to remain vigilant in the fight. ESCMID states that it is vital that new investments are made and we increase implementation of infection prevention and control strategies. Improved education and training is demanded, alongside further funding of R&D across new antibiotics, and crucially, increasing the durability of existing antibiotics through prudent use and antimicrobial stewardship.
The European Committee on Antimicrobial Susceptibility Testing — organized by ESCMID — functions as the breakpoint committee of EMA (European Medicines Agency) and ECDC, and will be announcing an update across European nations at this year’s congress.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance